COO · Cooper Companies

S&P 500 #444 · Nasdaq

Risiko 5/10 · Medical Device Restructuring · $72.06 ▲ 2.52%

Kennzahlen

• Price $72.06
• Market cap $14.1B
• P/E (ttm) 61.07
• Div yield none
• 52-wk range $58.89 – $89.83
• Index rank #444 / —

Wichtigste Risiken

• CooperSurgical Divestiture Uncertainty (Strategy) — MED
• High PE (60x) for Medical Device Sector (Valuation) — MED
• Litigation Charge Impact on Q2 Earnings (EPS) — MED
• Contact Lens Market Competitive Pressure (Pricing) — LOW

Fazit

Contact lens market leader (CooperVision) exploring sale of CooperSurgical unit; Q2 adjusted EPS of $1.21 beat $1.10 estimate by 10% despite litigation charge.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.